Differential expression of microtubule-associated protein 2 in melanocytic skin lesions

10Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Neoplastic melanocytes may exhibit certain differentiation characteristics of other neural-crest derivatives. We aimed to study the expression of microtubule-associatedprotein 2 (MAP-2) in different types of melanocytic skin lesions. Paraffin-embedded sections of 42 benign nevi (BN), 22 dysplastic nevi (DN), 45 superficial spreading melanomas (SSMs), and 15 subcutaneous melanoma metastases were immunohistologically assessed using the monoclonal mouse MAP-2ab antibody (Zytomed, Berlin, Germany). The percentage MAP-2 expression of DN and SSMs was significantly increased compared with BN. Moreover, subcutaneous melanoma metastases showed significantly decreased MAP-2 expression compared with DN and SSMs. In SSMs, MAP-2 expression significantly correlated with the Breslow vertical tumor thickness, Clark level, and stage of disease. We observed that MAP-2 is differentially expressed during the development and progression of benign and malignant melanocytic skin lesions. In contrast with the findings ofprevious studies, our data indicate that MAP-2 is a moderately positive predictor of the progression of SSMs. © American Society for Clinical Pathology.

Cite

CITATION STYLE

APA

Gambichler, T., Rotterdam, S., Radkowski, K., Altmeyer, P., & Kreuter, A. (2009). Differential expression of microtubule-associated protein 2 in melanocytic skin lesions. American Journal of Clinical Pathology, 131(5), 710–714. https://doi.org/10.1309/AJCPR84ULYVMNJHG

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free